Ernst doubles down on Medicaid comment with sarcastic video ‘apology'
Sen. Joni Ernst (R-Iowa) doubled down on a recent quip about Medicaid in a Saturday post on her Instagram story.
'Hello, everyone. I would like to take this opportunity to sincerely apologize for a statement that I made yesterday at my town hall,' Ernst said in the clip, with a sarcastic tone.
On Friday, the Iowa Republican was jeered after brushing aside life or death concerns about cuts to Medicaid, a public health insurance program for low income families and individuals with disabilities.
'See I was in the process of answering a question that had been asked by an audience member, when a woman who was extremely distraught, screamed out from the back corner of the auditorium, people are going to die,' Ernst said Saturday.
'And I made an incorrect assumption that everyone in the auditorium understood that, yes, we are all going to perish from this earth. So I apologize, and I'm really, really glad that I did not have to bring up the subject of the tooth fairy as well,' she continued.
The Iowa lawmaker then encouraged viewers who want to see 'eternal and everlasting life' to 'embrace' Jesus Christ.
During her Friday event in Butler, Iowa, Ernst promised that Republicans would 'protect' social services for the most vulnerable.
She suggested that those who work and have opportunity for benefits elsewhere 'receive those benefits elsewhere' and leave taxpayer dollars for those eligible for Medicaid.
Under the current GOP-House passed spending bill, millions would lose access to healthcare if passed by the Senate.
'Children will get hurt. Women will get hurt. Older Americans who rely on Medicaid for nursing home care and for home care will get hurt. People with disabilities who rely on Medicaid to survive will get hurt,' House Minority Leader Hakeem Jeffries said during the debate on the bill, according to Politico.
'Hospitals in your districts will close. Nursing homes will shut down. And people will die. That's not hype. That's not hyperbole. That's not a hypothetical,' he added.
Every Democrat who voted in the House, voted against the bill.
Some Senate Republicans have pledged to make some edits to the legislation, objecting to changes to Medicaid, the proposed phaseout of clean energy incentives and an increase in the federal debt.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fast Company
18 minutes ago
- Fast Company
From immigration law to business success: Navigating the challenges for foreign business in the U.S.
As a U.S. business immigration attorney and founder of Grape Law Firm PLLC, I have worked with many foreign entrepreneurs who have achieved lasting success in the United States. Establishing and scaling a company here requires time, effort, and strategic planning to navigate a complex web of immigration regulations and compliance requirements. COMMON LEGAL HURDLES IN SECURING EMPLOYEE VISAS The primary challenge faced by businesspeople is securing a legal presence in the United States. This means obtaining the appropriate visa or status for both entrepreneurs and their essential personnel. However, the process of business immigration to the U.S. is often a challenging adventure. According to the 2024 CIS Ombudsman Annual Report, from initial market entry to business expansion—and even to permanent establishment—the complexities of business immigration affect entrepreneurs at every stage of their U.S. journey. They face significant challenges in documenting the viability of their enterprises to immigration officials while managing their immigration status to meet the changing needs of the business ecosystem. NAVIGATING VISA PATHWAYS FOR BUSINESS GROWTH As business immigration attorneys, one of our primary duties is to help our clients choose the most suitable visa for their business vision and goals. The selection of the appropriate visa is the foundation on which a successful application strategy is built and is an investment in the company's long-term growth. It is imperative for entrepreneurs to understand that various options exist for starting new businesses in the United States or expanding existing operations. Each visa category has its own distinct advantages and considerations based on differing business needs. For instance, the E‑1 Treaty Trader and the E‑2 Treaty Investor visas are viable options for entrepreneurs. These visa categories cater to foreign traders and investors who are citizens of treaty countries—countries that have treaty agreements with the U.S. Traders must engage in continuous trade with the United States, and the U.S. must be their primary trading partner. Conversely, investors must make substantial investments through new or existing enterprises. Both the E‑1 and E‑2 visas can support long-term, sustainable business ventures in the United States (each is valid for up to five years and can be extended indefinitely), provided that they spur economic progress in their respective industries and investment areas. Furthermore, the L‑1 Intracompany Transferee visa is an ideal choice for international companies planning to expand to the U.S. The L‑1 visa allows foreign companies to transfer their managerial or executive employees for new office openings, thereby facilitating the establishment of operations in the United States. However, a potential downside is that the L‑1 visa requires rigorous application preparation—a thorough case file must be compiled, followed by consistently detailed documentation of organizational development and business growth metrics, especially during the first three years of operations. A CASE IN POINT One case from our L‑1 visa practice perfectly illustrates these complexities. As a seasoned professional in the scaffolding industry, our client's initial L‑1 New Office visa application succeeded through careful preparation and a comprehensive five‑year business plan. However, the real challenges emerged during the extension phase. When she sought to extend her L‑1 visa with different legal counsel, she faced a rigorous Request for Evidence (RFE) from USCIS that scrutinized every aspect of her business operations. The RFE questioned not only the structure, but also its growth trajectory and staffing decisions—common challenges that many foreign businesses face in proving the legitimacy and sustainability of their operations. The industry's unique characteristics, including its project‑based nature and specialized staffing requirements, made it particularly challenging to conform to USCIS's traditional expectations for business development. Her case is a stark reminder for prospective entrepreneurs that experienced immigration counsel can provide needed guidance throughout the ups and downs of their U.S. immigration journey. Entrepreneurs must acknowledge that deciding on the right visa type is more than an entry ticket to the United States—a visa is the key to legal rights, business investments, and financial aspirations that influence one's life in the U.S. BUILDING A FOUNDATION FOR LONG-TERM SUCCESS The U.S. business immigration ecosystem is ever-changing and demands legal acumen in business planning—integrating proactive immigration solutions from the very beginning. To achieve lasting success, entrepreneurs need expert legal guidance to navigate the complex steps of immigration and adapt to any changes or updates in the immigration system. Beyond legal counsel, success often hinges on comprehensive preparation and strategic planning. Maintaining detailed business documentation from day one proves crucial for immigration success. Successful immigrant entrepreneurs often distinguish themselves through meticulous record-keeping of business transactions, employee contracts, and market analyses that demonstrate their enterprise's viability. Early strategic planning should include developing detailed business projections, establishing clear organizational structures, and creating systems for tracking achievements and metrics. These elements strengthen visa applications and create a foundation for sustainable growth. Networking within industry associations and chambers of commerce can provide valuable insights into immigration processes and business development. Furthermore, entrepreneurs who actively participate in their industry's ecosystem often find themselves better positioned to demonstrate their legitimacy to immigration authorities. This comprehensive approach, combining thorough documentation with strategic foresight, guarantees that immigration planning aligns with business goals while maintaining strict compliance with U.S. regulations. As we look to the future, business expansion into the United States and immigration to the country will only become more interlinked. In that regard, the aforementioned success story of our entrepreneur client is an excellent example—showcasing that viewing immigration not as a hurdle but as a strategic tool is essential for success. Always remember: proper planning, combined with expert guidance, can transform potential obstacles into opportunities for growth in the American market. The key to sustainable success lies in developing a nuanced understanding of how immigration pathways can support business objectives while ensuring compliance with regulatory requirements.
Newsweek
19 minutes ago
- Newsweek
Number of Registered Democrats in Florida Falls to Record Low
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The number of Registered Democrats in Florida has fallen to a record low, new voting data has revealed. According to the Florida Division of Elections, the number of Democrats registered in the state has fallen compared to 2017. In the same time, the number of Republicans registered in the state has increased. Why It Matters Florida used to be a swing state but it has shifted toward Republicans in recent elections, President Donald Trump carrying it by 13 points against former Vice President Kamala Harris in the 2024 election. His margin in Florida was the largest for a presidential candidate in 36 years, with his 56 percent vote share being the sixth highest for the GOP in its history. Cementing a Republican shift will impact future election cycles. Former President Donald Trump stands on stage at the Republican Party of Florida Freedom Summit, Saturday, Nov. 4, 2023, in Kissimmee, Fla. Former President Donald Trump stands on stage at the Republican Party of Florida Freedom Summit, Saturday, Nov. 4, 2023, in Kissimmee, Fla. AP Photo/Phelan M. Ebenhack Sean Freeder, an assistant professor of political science at the University of North Florida, previously told Newsweek that changes in voting patterns can be attributed to long-term trends, such as older Americans who tend to vote Republican moving to Florida, as well as more recent shifts of Latinos and Cuban-Americans moving toward the Republican Party. What To Know According to the Florida Division of Elections, there are 4,329,371 active, registered Democratic voters. This is down from 4,479,820 in 2024 and more than 900,000 below the 5,315,954 registered in 2020. This is the smallest number of Florida Democrats in the state since at least 2017. The data is accurate as of April 30, 2025. As for the GOP, there are 5,578,457 Republican voters, up from 5,218,739 in 2020 and 4,544,708 in 2017. According to Michael Pruser, the director of data science with Decision Desk HQ, the latest voter rolls in Miami-Dade county show 464,370 registered Republicans, or 34 percent of voters while there are 440,790 Democrats, or 32.27 percent. Miami-Dade has leaned Democratic but has been trending closer to the right in recent elections. In August 2024, three months before the November 2024 presidential vote, election officials found that Florida has 1 million more Republican registered voters than Democrats. There were 5.3 million active Republican voters compared to 4.3 million active Democratic voters. Overall, Republicans now lead in 59 out of 67 counties in voter registration. However, changes in "list maintenance" laws have resulted in hundreds of thousands of voters—disproportionately registered as Democrats—being moved to "inactive" status, which removes them from active registration tallies so the figures may not reflect the actual number of Democrats in the state. What People Are Saying Kevin Wagner, political science professor at Florida Atlantic University, previously told Newsweek shifting national headwinds could "make things a little more volatile" for the midterms in Florida. "Midterms do tend to favor the party that does not hold the presidency. But, at this stage, the state Democrats probably have to think about rebuilding over multiple electoral cycles. They need to recruit and develop a larger group of potential candidates and build a better ground game with a more effective message. That's not likely to be fixed in one election," he said. Evan Power, chairman of the Republican Party of Florida, in a statement about Miami-Dade's voter roll data said: "This is a total repudiation of the Democrats' failed agenda. Miami-Dade is no longer their safe haven—it's the beating heart of the Republican revolution." "We're the party of hardworking families, Hispanic patriots, and communities demanding safe streets, top-notch schools, and a booming economy. Miami-Dade proves the unstoppable momentum of the Republican message." Florida Governor Ron DeSantis said on X: "A decade ago Miami-Dade county was a deep blue county with hundreds of thousands more registered Democrats than Republicans. "Today, the county—with more than 2.8 million people—has a Republican voter registration advantage. "Nobody would have predicted this ten years ago." A decade ago Miami-Dade county was a deep blue county with hundreds of thousands more registered Democrats than Republicans. Today, the county — with more than 2.8 million people — has a Republican voter registration advantage. Nobody would have predicted this ten years ago. — Ron DeSantis (@RonDeSantis) May 19, 2025 What Happens Next The number of Floridians who register as Republican or Democratic is likely to shift in the next months and years. The extent to which Florida favors either party will become clear when voters participate in the November 2026 midterm elections.
Forbes
19 minutes ago
- Forbes
Employers Reluctant To Cover Obesity Meds, Lower Costs May Change This
A new survey report from the International Foundation of Employee Benefit Plans shows continued reluctance by United States employers to cover glucagon-like peptide-1 drugs for weight loss. Going forward, however, lower net costs may induce better coverage by employers. Makers of GLP-1s for obesity are offering an array of discounts, some to insurers, others directly to patients. The IFEBP first conducted the survey in Oct. 2023 and again in May 2024. In the latest survey released ten days ago, employers revealed that 55% of them provide coverage of GLP-1s for diabetes only, while only 36% provide coverage for both diabetes and weight loss. And of those employers currently offering GLP-1 drug coverage solely for diabetes, just 17% are considering reimbursement of drugs for weight loss. Broadly speaking, the survey responses demonstrate that a large number of employers are still unwilling to reimburse GLP-1s for obesity. The weight loss therapeutics activate the body's receptors for GLP-1 on its own or in combination with GIP. When released by the gut, these natural hormones increase insulin delivery, suppress appetite, slow stomach emptying and increase the feeling of fullness. Perhaps what's driving continued reluctance to cover these products for weight loss is the overall impact that GLP-1s have on employers' pharmacy budgets. GLP-1 drugs used for obesity account for an average of 10.5% of total annual claims in the 2025 survey. In parts of the traditional health plans' market, we observe that some insurers are reconsidering their coverage of GLP-1s. Blue Cross Blue Shield, for example, just announced a reversal in its policy in which some plans offered coverage of GLP-1s for obesity. Starting in January 2026, BCBS will no longer cover these medicines for weight loss across the insurer's standard plans. At the same time, however, the large insurer Cigna announced it will begin capping out-of-pocket costs at $200 per month, starting next month, for patients using the obesity drugs Wegovy (semaglutide) and Zepbound (tirzepatide) through an add-on to its pharmacy benefit management plans. This is aimed at encouraging more employers to offer coverage of the drugs. It's unknown what the net cost to Cigna will be for the medicines. But presumably, the insurer has been able to reach a deal that's favorable financially, meaning a substantial reduction in net costs. It's possible in future that employers decide to revisit their coverage decisions if net costs decrease sufficiently, combined with more data showing the benefits of weight loss drugs when taken consistently and in conjunction with an appropriate dietary and exercise regimen. Also, the pharmaceutical firm Novo Nordisk announced last month a new partnership with CVS Caremark, the nation's largest pharmacy benefit manager, which grants coverage of Wegovy over its competitor Zepbound for customers who are insured for obesity medications. It's presumed that CVS was able to negotiate sizable rebates for Wegovy. CVS Caremark said that for insured patients, starting this July, Wegovy and Saxenda (liraglutide) will be the preferred GLP-1 medicines on its largest commercial formularies. This implies fewer access restrictions such as prior authorization, but also lower patient cost-sharing. It's unknown precisely what this means in terms of out-of-pocket costs for patients. But most patients with coverage for obesity drugs have monthly cost-sharing under $100. The arrangements reached by Cigna and CVS could help bring down net prices for employers for popular weight loss medicines. And at the same time, under the Inflation Reduction Act, the federal government is negotiating the prices of the GLP-1s Ozempic (semaglutide) and Wegovy. So-called maximum fair prices will be publicly posted in early 2026. These could reflect even steeper discounts. In addition to what payers are doing, Novo Nordisk is pursuing a direct-to-patient strategy to regain market share it has lost to drug maker Eli Lilly in the lucrative obesity drug market. Here, Novo Nordisk struck a deal in which CVS pharmacy will offer Wegovy for $499 a month for cash-paying customers who aren't insured for the medication. Since the Food and Drug Administration removed the active ingredients semaglutide and tirzepatide from its shortage list, the business model of selling directly at a considerable discount to the consumer has become popular for the two main manufacturers of obesity drugs. In 2024, Eli Lilly adopted a direct-to-consumer strategy for Zepbound, among other products, with its LillyDirect program. This service includes a DTC pharmacy and a referral network of in-person and telehealth clinicians. LillyDirect allows uninsured or underinsured individuals not on Medicaid or Medicare to purchase Zepbound product directly after obtaining the requisite prescription from their doctor. The firm recently extended the range of Zepbound products available through LillyDirect by adding high-dose vials at $499. Rival Novo Nordisk also launched a DTC option, NovoCare Pharmacy, two months ago. Patients not insured in the public sector who wish to have access to Wegovy can acquire the drug for an out-of-pocket cost of $499 per month, provided they have a prescription and make use of a designated specialty pharmacy. And, since the end of April, customers also pay a $499 monthly subscription when they obtain Wegovy from Ro and LifeMD, and $599 at Hims & Hers. While employers aren't yet reimbursing weight loss drugs en masse, significantly reduced net costs could affect their future coverage decisions.
